Serum macrophage colony-stimulating factor levels in patients with essential hypertension after vaccination against SARS-CoV-2

Cover Page

Cite item

Abstract

The formation of immunity in the population to various variants of the COVID-19 pathogen is one of the most important problems for the world community. The aim of the study was to compare the dynamics of M-CSF and VEGF-A, IL-34 in the blood serum of patients with essential hypertension (EH) stage II, depending on the type of immunity formed (post-infectious, post-vaccination, “hybrid”) to analyze changes of M-CSF-mediated mechanisms of hypertension development. During the work, 2 groups of patients were formed: group 1-patients with stage II EH and SARS CoV-2 infection without pneumonia in the anamnesis, vaccination 6 months after laboratory recovery, group 2 – patients with stage II EH without COVID-19 in the anamnesis, vaccination during the follow-up period. Determination of M-CSF, IL-34, VEGF-A, IgG level to SARS-CoV-2 was determined using an enzyme-linked immunosorbent assay. The formation of post-infectious immunity in patients with stage II EH, despite the mild course of COVID-19, is accompanied by a long-term (up to 6 months) pathophysiologically significant increase in the serum level of M-CSF (p < 0.001) with a decrease in IL-34 (p < 0.001). Analysis of the dynamics of changes in M-CSF, IL-34, VEGF-A in the postvaccination period in the blood serum of patients with stage II EH with COVID-19 in the anamnesis (“hybrid” immunity), determined the absence (p < 0.05) of changes in the levels of M-CSF, VEGF-A after the first component of “SPUTNIK V” against the background of an increase of the level of IgG to SARS-CoV-2. 21 days after the second component of the vaccine, an increase of M-CSF was detected when compared with both pre-vaccination indicators and data 21 days after the introduction of the first component of the vaccine (p < 0.001). Comparing the dynamics of the of M-CSF, IL-34 and VEGF-A in patients with stage II EH without COVID-19 in the post-vaccination period with the data on the formation of “hybrid” immunity, an increase in M-CSF was recorded 21 days after the introduction of the first and second components against the background of a decrease in IL-34, but with the restoration of pre-vaccination concentrations in 100% of patients by day 180 with comparable immunogenicity after 180 days. In patients with EH II, the pathogenetic “summation” of the pre-infectious imbalance of cytokine regulation and postcovid changes is important, which in a number of patients may be the reason for the prolongation of the stabilization of the balance of the M-CSF-IL-34-VEGF-A system in the post-vaccination period during the formation of “hybrid” immunity.

About the authors

O. A. Radaeva

N. Ogarev National Research Mordovia State University

Author for correspondence.
Email: vtlbwbyf_79@mail.ru
ORCID iD: 0000-0002-0533-7652

PhD, MD (Medicine), Associate Professor, Professor, Department of Immunology, Microbiology and Virology

430000, Russian Federation, Saransk, Ulyanov str., 26a

Phone: 7 (8342) 3-21-98 

Russian Federation

A. S. Simbirtsev

State Research Institute of Highly Pure Biopreparations, Federal Medical-Biological Agency

Email: a.s.simbirtsev@hpb.spb.ru
ORCID iD: 0000-0002-8228-4240

 PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Chief Research Associate

St. Petersburg 

Russian Federation

Yu. A. Kostina

N. Ogarev National Research Mordovia State University

Email: bazunova.2013@mail.ru

 PhD (Medicine), Associate Professor, Department of Immunology, Microbiology and Virology

Saransk 

Russian Federation

M. S. Iskandyarova

N. Ogarev National Research Mordovia State University

Email: mashenkademjashkina@rambler.ru

 Assistant Professor, Department of Immunology, Microbiology and Virology

Saransk 

Russian Federation

S. V. Mashnina

N. Ogarev National Research Mordovia State University

Email: svetlana_belyaeva93@mail.ru

 Postgraduate Student, Department of Immunology, Microbiology and Virology

Saransk 

Russian Federation

E. V. Negodnova

N. Ogarev National Research Mordovia State University

Email: el.negodnova@gmail.com

Assistant Professor, Department of Immunology, Microbiology and Virology

Saransk 

Russian Federation

D. D. Besheynov

N. Ogarev National Research Mordovia State University

Email: besssheynovdd@mail.ru

Postgraduate Student, Department of Immunology, Microbiology and Virology

Saransk 

Russian Federation

References

  1. Радаева О.А., Симбирцев А.С., Селезнева Н.М., Искандярова М.С. Изменение уровня макрофагального колониестимулирующего фактора в сыворотке крови пациентов с эссенциальной гипертензией после SARS-COV-2 инфицирования // Российский иммунологический журнал. – 2020. – Т. 23, № 4. – С. 429-436.
  2. Babapoor-Farrokhran S., Gill D., Walker J., Rasekhi R.T., Bozorgnia B., Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci., 2020, Vol. 15, no.253, pp. 117723-117731.
  3. Berg, K.E, Ljungcrantz I., Andersson L., Bryngelsson C., Hedblad B., Fredrikson G.N., Nilsson J, Björkbacka H. Elevated CD14++CD16‐ monocytes predict cardiovascular events// Circ. Cardiovasc. Genet., 2012, Vol. 5, pp. 122-131.
  4. Carod-Artal F.J. Neurological complications of coronavirus and COVID-19. Rev Neurol., 2020, Vol. 70, no. 9, pp. 311‐322.
  5. Crotty S. Hybrid immunity. Science, 2021, Vol. 372 (6549), pp. 1392-1393.
  6. Frieman M., Harris A.D., Herati R.S., Krammer F., Mantovani A., Rescigno M., Sajadi M.M., Simon V. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine, 2021, Vol. 68, pp. 103401-103409
  7. Guzik,T. J., Mohiddin S. A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F. M., Madhur M. S., Tomaszewski M., Maffia, P., D'Acquisto F., Nicklin S. A., Marian A. J., Nosalski R., Murray E. C., Guzik B., Berry C., Touyz R. M., Kreutz R., Wang D. W., Bhella D., McInnes I. B. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res., 2020, Vol. 116, no. 10, pp. 1666-1687.
  8. Muñoz-Garcia J., Cochonneau D., Télétchéa S., Moranton E., Lanoe D., Brion R., Lézot F., Heymann M.F., Heymann D. The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. Theranostics, 2021, Vol. 11(4), pp. 1568-1593.
  9. Okazaki T., Ebihara S., Asada M., Yamanda S., Saijo Y., Shiraishi Y., Ebihara T., Niu K., Mei H., Arai H., Yambe T. Macrophage colony-stimulating factor improves cardiac function after ischemic injury by inducing vascular endothelial growth factor production and survival of cardiomyocytes. Am. J. Pathol., 2007, Vol. 171, pp. 1093-1103.
  10. Petrone L., Petruccioli E., Vanini V., Cuzzi G., Najafi Fard S., Alonzi T., Castilletti C., Palmieri F., Gualano G., Vittozzi P., Nicastri E., Lepore L., Antinori A., Vergori A., Caccamo N., Cantini F., Girardi E., Ippolito G., Grifoni A., Goletti D. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect., 2021, Vol. 27(2):286.e7-286.e13.
  11. Radaeva, O.A., Simbirtsev, A.S., Kostina, J.A. The change in the circadian rhythm of macrophage colony-stimulating factor content in the blood of patients with essential hypertension. Cytokine: X, 2019, Vol. 1, no. 3.
  12. Schiopu A., Bengtsson E., Gonçalves I., Nilsson J., Fredrikson G.N., Björkbacka H. Associations Between Macrophage Colony-Stimulating Factor and Monocyte Chemotactic Protein 1 in Plasma and First-Time Coronary Events: A Nested Case-Control Study. J Am Heart Assoc. 2016, Vol, 5, no. 9, e002851

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Radaeva O.A., Simbirtsev A.S., Kostina Y.A., Iskandyarova M.S., Mashnina S.V., Negodnova E.V., Besheynov D.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Свидетельство о регистрации СМИ ПИ № 77 - 11525 от 04.01.2002 выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies